STUDY OBJECTIVES

- Primary Objective
  - Randomization stratified by:
    - Receipt of an allowed prior antibiotic limited to ≤72 hours prior to test article administration because of CABP (ITT population)
    - PORT Risk Class II limited to ≤7 days
  - Portion of prior antibiotics (ITT population)

- Indicate that the study was designed to evaluate:
  - Safety
  - Tolerability
  - Clinical Success
  - Pharmacodynamics
  - Pharmacokinetics

- Indicate the primary endpoint

- Descriptive statistics

- Percentages

- Continuous variables

- Categorical variables

- Discrete variables

- Outcome measures

- Sample size

- Statistical methods

- Analysis of data

- Interpretation of results

- Conclusion

- Recommendations

- Limitations

- Future research

- Acknowledgments

- References

- Funding and disclosures

ACKNOWLEDGMENTS

The OPTIC study was funded by Paratek Pharmaceuticals, Inc.

REFERENCES

3. Joven Gonong, MD3; Ismail Mitha, MD4
5. Joven Gonong, MD3; Ismail Mitha, MD4
6. Andrzej Madej, MD, PhD6
7. Paul McGovern, MD

FUNDING AND DISCLOSURES

To the best of the authors’ knowledge, no potential conflicts of interest related to this study were reported.

Acknowledgments

Paratek Pharmaceuticals, Inc.

Presented at IDWeek 2017; October 4-8, 2017; San Diego, CA.